Prabhudas Lilladher has come out with its first quarter (April-June’ 19) earnings estimates for the Pharma sector. The brokerage house expects Jubilant Life Sciences to report net profit at Rs. 181.4 crore down 10.4% year-on-year (up 33.9% quarter-on-quarter).
Net Sales are expected to increase by 13 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 2,348.5 crore, according to Prabhudas Lilladher.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 1.5 percent Y-o-Y (up 20.4 percent Q-o-Q) to Rs. 431 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
PL - Consolidated Earnings Estimates
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
